Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Diagnostics Startup CeMines Closes First Round of Funding

NEW YORK, March 2 (GenomeWeb News) - CeMines, a molecular diagnostics and therapeutics startup based in Evergreen, Colo., has closed Round A funding in the "low seven figures," a company spokesman said today.

CeMines CEO Bailey Dotson said the company is "within 60 days of mass production" for a test kit for the early detection of cancer based on its Molecular FingerPrinting technology, which detects antibodies produced by the body in response to early-stage cancer.

Dotson said that the test kit will be used in large-scale clinical trials at "several world-class medical facilities." According to the company's website, CeMines will price its tests between $100 and $500 each.

CeMines plans to use the Round A private-placement financing to "fast forward" development of the cancer detection test, Dotson said. Discussions for a Round B funding are underway, she added. The company expects to complete that round of funding by the end of the summer.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.